New Study for K-Ras Stage IV : Enroll THIS WEEK!
dianetavegia
Member Posts: 1,942 Member
Click Here for full article
The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST).
The open-label, 56-patient KRAS-mutated colorectal cancer study is being conducted at three U.S. locations. Patient enrollment begins this week. All subjects will receive Imprime PGG® at 4 mg/kg weekly plus standard doses of Erbitux®. Tumor measurements and determination of tumor responses for this study will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST).
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 122.2K Cancer specific
- 2.8K Anal Cancer
- 450 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 399 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 676 Leukemia
- 797 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 240 Multiple Myeloma
- 7.2K Ovarian Cancer
- 65 Pancreatic Cancer
- 492 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 543 Sarcoma
- 739 Skin Cancer
- 658 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards